Japan puts $8M behind nasal TB vax; 1.25 million child study shows no vaccine-autism link;

> Japan's state-backed Innovation Network is leading an ¥845 million ($8.3 million) round of investment in Create Vaccine, a TB vax developer, to fund the creation of a nasal vaccine for adults. Report

> A watered-down attempt to boost vaccination rates has been signed into law in Colorado. More

> Germany has provided Malawi with a €5 million grant to support the country's immunization program. More

> The Medical Affairs Committee of the South Carolina Senate has passed a bill aimed at encouraging parents to get their children vaccinated against human papillomavirus (HPV). More

> The FDA has approved a Campylobacter jejuni vaccine for human trials. Report

> Researchers report that delaying the first measles-mumps-rubella vaccine (MMR) or the first measles-mumps-rubella-varicella vaccine (MMRV) beyond the age of 15 months may more than double a 2-year-old's risk for postvaccination seizures, researchers report. More (reg. req.)

> Administering Merck's ($MRK) rotavirus jab RotaTeq to infants in the neonatal intensive care unit appears to be safe, a new study shows. Report (reg. req.)

> A series of vaccine injections given directly into a pancreatic cancer tumor has been well tolerated and suggests a period of stable disease, according to eesearch from Rutgers Cancer Institute. News

And Finally... A new Australian study of 1.25 million children around the world shows no link between vaccines and autism. More

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.